SeaStar Medical (NASDAQ:ICU) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of SeaStar Medical (NASDAQ:ICU) to a hold rating in a report published on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of SeaStar Medical in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

SeaStar Medical Stock Performance

SeaStar Medical stock opened at $2.26 on Friday. The company has a market capitalization of $8.15 million, a P/E ratio of -0.14 and a beta of -1.00. SeaStar Medical has a fifty-two week low of $2.20 and a fifty-two week high of $30.70. The stock has a 50-day simple moving average of $3.30 and a 200-day simple moving average of $5.80.

SeaStar Medical (NASDAQ:ICU) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($1.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.50) by $0.20. The company had revenue of $0.18 million during the quarter, compared to analysts’ expectations of $0.25 million. SeaStar Medical had a negative return on equity of 414.50% and a negative net margin of 1,551.08%.

Institutional Investors Weigh In On SeaStar Medical

A number of hedge funds have recently added to or reduced their stakes in the company. Trinity Financial Advisors LLC raised its stake in shares of SeaStar Medical by 233.3% during the 3rd quarter. Trinity Financial Advisors LLC now owns 50,000 shares of the company’s stock worth $28,000 after buying an additional 35,000 shares in the last quarter. XTX Topco Ltd lifted its holdings in SeaStar Medical by 395.4% in the second quarter. XTX Topco Ltd now owns 60,983 shares of the company’s stock valued at $26,000 after acquiring an additional 48,674 shares during the period. Finally, Millennium Management LLC purchased a new stake in shares of SeaStar Medical during the 3rd quarter worth $102,000. Institutional investors and hedge funds own 1.69% of the company’s stock.

About SeaStar Medical

SeaStar Medical, Inc (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.

The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR.